BOSTON, MA — January 5, 2026 — Leads & Copy — Medzown, a precision medicine management company, has announced the appointment of Jennifer Malin, M.D., Ph.D., as its Chief Medical Officer.
In her new role, Dr. Malin will spearhead Medzown’s clinical strategy and precision medicine programs, focusing on integrating multifactorial data to connect patients with relevant clinical trials.
Dr. Malin brings over 15 years of experience in designing and implementing value-based care initiatives across oncology, rare disease, precision medicine, and population health. Her expertise includes coverage and reimbursement strategy, alternative payment models, and the adoption of novel therapies and technologies.
“I am honored to join Medzown at such a pivotal time for precision medicine, therapeutic innovation, and the urgent need for strategies to mitigate rising healthcare costs,” said Dr. Malin. She emphasized Medzown’s platform’s unique alignment of advanced science, real-world data, and patient navigation to expedite patient access and enrollment in clinical trials.
Dr. Jennifer Levin Carter, Founder and Chief Executive Officer of Medzown, highlighted Dr. Malin’s track record of building large-scale clinical and value models. She noted that Dr. Malin’s experience in shaping national oncology and rare disease programs at leading health plans aligns with Medzown’s future direction.
Prior to joining Medzown, Dr. Malin was Senior Vice President and Chief Medical Officer of Optum Health Solutions, where she led teams responsible for developing clinical programs to improve outcomes and value for patients with complex conditions, including cancer and rare diseases. She also led the development and implementation of value-based care programs in oncology and genetics at United Healthcare and launched Anthem’s Cancer Care Quality Program.
Dr. Malin has authored over 100 peer-reviewed articles and has served on committees such as the American Society of Clinical Oncology’s Quality of Care Committee. She also maintains a part-time clinical practice in oncology at the VA Medical Center in West Los Angeles.
Medzown, founded in 2022, focuses on expanding access to advanced therapies and clinical trials for patients with cancer and other high-cost, complex diseases. Its platform combines advanced data analytics with clinical guidance to match patients with appropriate therapies and clinical trials.
Each case is reviewed by PhD scientists and supported by navigators who work directly with patients and their physicians.
Jessica Starman, MBA
media@medzown.com
Source: Medzown
